H Delta Private Equity Partnership agreed to acquire 24.4% stake in Contera Pharma ApS from Bukwang Pharmaceutical Co., Ltd. (KOSE:A003000) for KRW 6.3 billion on March 22, 2024. The transaction will be funded from retained funds and borrowings. Contera Pharma reported net loss of KRW 13.7 billion, total debt of KRW 1.2 billion and total assets of KRW 17.7 billion in 2023. The transaction is expected to close on April 1, 2024.

H Delta Private Equity Partnership completed the acquisition of 24.4% stake in Contera Pharma ApS from Bukwang Pharmaceutical Co., Ltd. (KOSE:A003000) on April 1, 2024.